DDInter419 DDInter927
Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia. However, its promiscuity toward the muscarinic and adrenergic receptors can result in other side effects, notably gastrointestinal hypomotility and orthostatic hypotension. [L905,A215552]. Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.[A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Clozapine {u} (Compound) resembles {v} (Compound) Trifluoperazine
Clozapine {u} (Compound) resembles {v} (Compound) Prochlorperazine
Clozapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azatadine
Clozapine {u} (Compound) binds {v} (Gene) CYP2D6
Clozapine {u} (Compound) upregulates {v} (Gene) ST3GAL5
Clozapine {u} (Compound) palliates {v} (Disease) bipolar disorder
Clozapine {u} (Compound) downregulates {v} (Gene) POLR2I
Clozapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Clozapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Caffeine
Clozapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trospium
Clozapine (Compound) resembles Trifluoperazine (Compound)
Clozapine (Compound) resembles Prochlorperazine (Compound)
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Clozapine (Compound) binds CYP2D6 (Gene)
Clozapine (Compound) upregulates ST3GAL5 (Gene)
Clozapine (Compound) palliates bipolar disorder (Disease)
Clozapine (Compound) downregulates POLR2I (Gene)
Clozapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Clozapine may cause a minor interaction that can limit clinical effects when taken with Caffeine
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Trospium